Type 1 diabetes treatment may soon move beyond the liver as researchers tackle a critical engineering challenge that has limited alternative transplant approaches. Current islet cell transplantation delivers insulin-producing cells directly into the liver, where they face immediate inflammatory damage and long-term complications from immunosuppressive drugs.
Bioengineers tested biodegradable polymer scaffolds designed to house transplanted islet cells in the omentum, a protective abdominal membrane. The poly(lactide-co-glycolide) structures showed promising results in mouse models, restoring normal blood sugar levels. However, when scaled to nonhuman primates, gamma irradiation sterilization—required for clinical safety—significantly compromised scaffold integrity. The sterilized scaffolds became fragile during surgical handling and showed reduced effectiveness in controlling diabetes despite containing viable insulin-producing cells after four weeks.
The research team discovered that adjusting the polymer-to-salt manufacturing ratio from 1:30 to 1.25:30 improved structural durability without altering the scaffold's porous architecture. Further optimization identified a 1.15:30 ratio as the optimal balance between mechanical stability and biological compatibility in mouse studies.
This work addresses a fundamental challenge in regenerative medicine: maintaining device performance through necessary sterilization processes. While extrahepatic islet transplantation remains promising for reducing diabetes complications, the findings highlight how manufacturing details can determine clinical success. The research provides a framework for optimizing biomaterial scaffolds that must withstand both sterilization and surgical manipulation while supporting long-term cell survival and function.